FDA includes CV benefits of Novo’s Victoza in label
The ability to reduce the risk of major cardiovascular events is now included in the US label for Novo Nordisk’s diabetes drug Victoza, giving the pharma company a “great competitive edge”, according to one analyst.
BY RITZAU FINANS & MARTIN HAVTORN PETERSEN
Novo Nordisk has secured an important sales argument for its best-selling drug, GLP-1 analogue Victoza, on the US market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo rival disappoints in major cardiovascular study
For abonnenter
